The global vaginitis therapeutics market size was valued at USD 2.20 billion in 2017 and is anticipated to expand at a CAGR of 8.4% during the forecast period. Increasing awareness about women’s health, introduction of new drugs by key companies, and rising demand for improved healthcare infrastructure are some of the major factors driving the market.
According to the Centers for Disease Control and Prevention (CDC), in 2015, more than 13 of every 100 women were cigarette smokers. The National Institute of Allergy and Infectious Diseases (NIAID) funded scientists to develop the test for yeast infection to provide appropriate anti-fungal treatment. In addition, NICHD researchers within the Division of Intramural Population Health research (DIPHR) are using previous and newly collected data to explore various aspects of association between bacterial vaginosis and pregnancy outcome. Rise in research and development activities for accurate diagnosis is projected to boost market growth. Various government and non-government organizations, such as Women Health Organization and European Institute of Women’s Health (EIWH), have undertaken initiatives to increase awareness regarding women’s health. Continuous research and development activities by various companies and changing lifestyle pattern of women across the globe, such as smoking and alcohol consumption, are the key factors driving the market growth.
On the basis of product, vaginitis therapeutics market is segmented into anti-fungal, anti-bacterial, and hormone. Anti-bacterial segment held the largest market share owing to rising cases of bacterial vaginosis. Anti-bacterial market was valued at USD 900 million in 2017, in terms of revenue. It was reported that around 21 million women were suffering from this problem. Drugs used for the treatment of bacterial vaginosis metronidazole, clindamycin, and tinidazole.
While hormonal treatment segment is expected to witness the fastest growth over the forecast period. Most of the hormonal treatments are available only through prescription. The presence of strong pipeline drugs is expected to support the segment’s fastest growth over the forecast period.
On the basis of type, the market is categorized into Over-The-Counter (OTC) and prescription (Rx). Among these, prescribed type accounts for the largest market share owing to higher efficacy and safety for severe and recurring vaginitis. OTC is expected to expand at a CAGR of 8.7% during the estimated period due to the presence of a wide range of OTC drugs, such as vaginal creams, gels, and others. Furthermore, for non-prescribed drugs, FDA has approved treatment options for mild vaginitis for external use. These include tioconazole miconazole, clotrimazole, and butoconazole in the form of cream, tablets, and suppositories.
North America led the global market in 2017 and was valued at USD 861.2 million. Established healthcare infrastructure in this region along with high prevalence of disease and the presence of key manufacturers is a major factor responsible for its largest share. Other factors, such as favorable government initiatives and growing target population are also propelling the market growth.
Asia Pacific is estimated to witness the fastest growth with CAGR of around 9.6% during the forecast period. This is attributed to high unmet clinical needs, rising disposable income increased awareness about early diagnosis, and availability of effective drugs in emerging countries, such as India and China.
Key companies in this industry are Pfizer, Inc.; Merck & Co.; Novartis AG; Bayer AG; Lupin Pharmaceuticals, Inc.; Symbiomix Therapeutics, Inc.; and Mission Pharmacal Company.
Most of these companies are adopting strategies, such as collaborations, new drug development, M&A, business expansion in emerging regions. For instance, in October 2017, Lupin Pharmaceuticals acquired Symbiomix Therapeutics to increase its product portfolio. In October 2017, Pfizer Inc. announced the review of strategic alternative for spin off its Consumer Healthcare Business as a strategic initiative.
Report Attribute |
Details |
Market size value in 2020 |
USD 2.7 billion |
Revenue forecast in 2025 |
USD 4.2 billion |
Growth Rate |
CAGR of 8.4% from 2018 to 2025 |
Base year for estimation |
2017 |
Historical data |
2014 - 2016 |
Forecast period |
2018 - 2025 |
Quantitative units |
Revenue in USD Million & CAGR from 2018 to 2025 |
Report coverage |
Revenue forecast; company share; competitive landscape; growth factors and trends |
Segments covered |
Product, type, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; Japan; China; Brazil; Mexico; and South Africa |
Key companies profiled |
Pfizer, Inc.; Merck & Co.; Novartis AG; Bayer AG; Lupin Pharmaceuticals, Inc.; Symbiomix Therapeutics, Inc.; Mission Pharmacal Company. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country; regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global vaginitis therapeutics market report on the basis of product, type, and region:
Product Outlook (Revenue, USD Million, 2014 - 2025)
Anti-fungal
Anti-bacterial
Hormone
Type Outlook (Revenue, USD Million, 2014 - 2025)
Over-The-Counter (OTC)
Prescription (Rx)
Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
The U.S.
Canada
Europe
Germany
The U.K.
Asia Pacific
Japan
China
Latin America
Brazil
Mexico
MEA
South Africa
b. The global vaginitis therapeutics market size was estimated at USD 2.5 billion in 2019 and is expected to reach USD 2.7 billion in 2020.
b. The global vaginitis therapeutics market is expected to grow at a compound annual growth rate of 8.4% from 2017 to 2025 to reach USD 4.2 billion by 2025.
b. North America dominated the vaginitis therapeutics market with a share of 38.7% in 2019. This is attributable to established healthcare infrastructure in this region along with high prevalence of disease and presence of key manufacturers.
b. Some key players operating in the vaginitis therapeutics market include Pfizer, Inc.; Merck & Co.; Novartis AG; Bayer AG; Lupin Pharmaceuticals, Inc.; Symbiomix Therapeutics, Inc.; and Mission Pharmacal Company.
b. Key factors that are driving the market growth include increasing awareness about women’s health, introduction of new drugs by key companies, and rising demand for improved healthcare infrastructure.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.